PatentsSkinny Labeling may Still Cause an Infringement – Decision of the US Court of Appeals
April 21, 2025
Federal Circuit Revives Amarin’s Induced Infringement Case Against Hikma Over Vascepa® Generic* In a significant decision for pharmaceutical patent litigation, the U.S. Court of Appeals for the Federal Circuit has reinstated Amarin Pharma’s lawsuit against Hikma Pharmaceuticals. The court found that Amarin had plausibly alleged Hikma’s conduct induced infringement of patents tied to the cardiovascular...
